|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期- |
A Phase 2, Randomized, Placebo-Controlled Trial to Assess the Efficacy and Safety of Mosliciguat in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
100 项与 Pulmovant, Inc. 相关的临床结果
0 项与 Pulmovant, Inc. 相关的专利(医药)
100 项与 Pulmovant, Inc. 相关的药物交易
100 项与 Pulmovant, Inc. 相关的转化医学